30 November 2023
30 November 2023
Following the approval of NiCord earlier this year, there are more candidates coming to late-stage trials looking to target GvHD.
AbbVie is currently enrolling NSCLC patients into a Phase III trial investigating Teliso-V as a monotherapy.
The placebo-controlled Phase II trial will evaluate setanaxib as a treatment for Alport syndrome, a rare genetic kidney disorder.
4Moving Biotech will use different endpoints and an in-silico add-on trial to investigate 4P004 in the upcoming Phase IIb trial.
Closing the first day of the CTO Europe conference, a global CRO shares insights on the drug development lifecycle in oncology.
The health authority has given the go-ahead for Part 1c of the PRO-101 trial investigating the use of prosetin in participants with ALS.
The trial intends to analyse the tolerability, safety, pharmacodynamics, and pharmacokinetics of ARO-DM1.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
